Yazar "Aktürk E." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Cardiovascular effects of cancer drugs: Review
    (Turkiye Klinikleri, 2014) Aktürk E.; Kurto?lu E.; Ermiş N.
    Widening the array of active antineoplastic agents has resulted in a prolongation of lifespan of cancer patients, but also increased the possibility of manifestation of adverse effects of anticancer treatment. Cardiovascular toxicity is a potential short- or long-term complication of anticancer therapy. The mechanisms of particular cardiovascular toxicities in cancer patients may differ from those of general population and the presence of cancer may limit the therapeutic options. Therefore, general treatment guidelines in cardiovascular disorders may not be appropriate in cancer patients. Additionally, cardiovascular toxicities reported in clinical trials do not always reflect those of "real world" patients. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardiooncologic" investigators. Cardiac toxicity associated with cancer therapies can range from asymptomatic subclinical abnormalities, including electrocardiographic changes and temporary left ventricular ejection fraction decline, to life-threatening events such as heart failure or acute coronary syndromes. The aim of this review is to summarize potential cardiovascular toxicities for a range of cancer chemotherapeutics. Given the rate of new drug development designed to fulfill unmet oncologic needs, efforts are needed to promote strategies for cardiac risk detection and management and to avoid unintended consequences potentially impeding development of, regulatory approval for, manage the cardiovascular safety of patients treated with anticancer agents, as well as a well-organized collaboration between oncologists and cardiologists. Copyright © 2014 by Türkiye Klinikleri.
  • Küçük Resim Yok
    Öğe
    Evaluation of the relationship between serum high sensitive C-reactive protein and the elasticity properties of the aorta in patients with coronary artery ectasia
    (AVES, 2011) Sincer I.; Aktürk E.; Açikgöz N.; Ermiş N.; Koşar M.F.
    Objective: Previous studies have shown an association between high sensitive C-reactive protein (hsCRP) and arterial stiffness in most cardiovascular diseases. High sensitive C-reactive protein and arterial stiffness have been considered as independent predictors of cardiovascular mortality in cardiovascular disease. The aim of this study was to investigate the relationship between hsCRP, a marker of systemic inflammation and aortic stiffness in patients with coronary artery ectasia (CAE). Methods: Our study was designed as cross-sectional study. Serum hsCRP levels and aortic stiffness parameters were measured in CAE patients (n=28) and age - and gender-matched control subjects (n=25). Serum hsCRP levels were determined by an immunonephelometry assay. Aortic strain (AS) and aortic distensibility (AD) were calculated from the aortic diameters measured using M-mode echocardiography and blood pressure obtained by sphygmomanometry. Independent samples "t" test, Chi-square test and Spearman correlation test were used for statistical analysis. Results: Serum levels of hsCRP in CAE group were higher than in the controls (p<0.001). AS and AD were significantly decreased in CAE patients compared to the controls (p<0.001 and p<0.001, respectively). There were negative correlations between hsCRP and AS (r=-0.862; p<0.001), and AD (r=0.852; p<0.001) and a positive correlation between hsCRP, and ASI (r=0.852; p<0.001). Conclusion: We have demonstrated that there is a significant correlation between serum hsCRP levels and aortic stiffness in patients with CAE. These findings may indicate an important role of hsCRP in the pathogenesis of impaired aortic stiffness in coronary ectasia. ©Copyright 2011 by AVES Yaynclk Ltd.